Drug comparisons
Linagliptin vs Lixisenatide
Linagliptin vs Lixisenatide for T2 diabetes: oral DPP-4 inhibitor vs GLP-1 agonist injection. Compare A1C, weight, GI side effects, and convenience.
No comparison dimensions are available for this page.
Clinical context
This comparison is triggered when selecting add-on or combination therapy for type 2 diabetes between a DPP-4 inhibitor and a GLP-1 receptor agonist.
Bottom line
Linagliptin offers convenient oral use with a milder side-effect profile, whereas Lixisenatide provides weight-loss potential but requires injection.
All medication comparisons